References

  1. Goicoechea M, Best B. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all. Expert Opin Pharmacother. 2007; 8(3): 371-82. PubMed | Google Scholar

  2. WHO. WHO guidelines approved by the guidelines review committee, in consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization: Geneva. 2013. Google Scholar

  3. Calza L et al. Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir or lopinavir/ritonavir. Scand J Infect Dis. 2013; 45(2): 147-54. PubMed | Google Scholar

  4. Soler-Palacin P et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. Aids. 2011; 25(2): 171-6. PubMed | Google Scholar

  5. Mathew G, Knaus SJ. Acquired fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med. 2006; 21(11): C3-5. PubMed | Google Scholar

  6. Herlitz LC et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological and mitochondrial abnormalities. Kidney Int. 2010; 78(11): 1171-7. PubMed | Google Scholar

  7. Zimmermann AE et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006; 42(2): 283-90. PubMed | Google Scholar

  8. Gupta SK et al. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS One. 2014; 9(3): e92717. PubMed | Google Scholar

  9. Tourret J, Deray G, Isnard-bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword. J Am Soc Nephrol. 2013; 24(10): 1519-27. PubMed | Google Scholar

  10. Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014; 70(9): 1029-40. PubMed | Google Scholar

  11. Pujari SN et al. Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom. BMC Infect Dis. 2014; 14: 173. PubMed | Google Scholar

  12. Patel KK et al. Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis. 2010; 31(1): 30-4. PubMed | Google Scholar

  13. Krishna MM et al. Delayed onset renal failure in a patient on tenofovir based antiretroviral regimen. Indian J Pharmacol. 2014; 46(2): 230-1. PubMed | Google Scholar

  14. Irizarry-Alvarado JM et al. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read. 2009; 19(3): 114-21. PubMed | Google Scholar

  15. Cooper RD et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010; 51(5): 496-505. PubMed | Google Scholar

  16. Ryom L et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D: A: D Studya. J Infect Dis. 2013; 207(9): 1359-69. PubMed | Google Scholar

  17. Fernandez-Fernandez B et al. Tenofovir nephrotoxicity: 2011 update. AIDS res treat. 2011. Google Scholar

  18. Young J et al. The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Med. 2014. Google Scholar

  19. Liborio AB et al. Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney int. 2008; 74(7): 910-8. PubMed | Google Scholar

  20. Wever K, Van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J acquir immune defic syndr. 2010; 55(1): 78-81. PubMed | Google Scholar